How do specialists decide if glaucoma is progressing? 

Determining whether glaucoma is progressing is one of the most critical aspects of long-term ophthalmic care. Because glaucoma is a chronic, degenerative condition, a single eye examination provides only a snapshot in time. To decide if the disease is moving forward, specialists must compare data across multiple visits to identify trends that indicate a loss of nerve tissue or a decline in visual function. In the United Kingdom, this process is known as longitudinal monitoring. Clinicians look for a “rate of change” that exceeds what would be expected for a person’s age. If the structural integrity of the optic nerve is thinning or if new blind spots are appearing in the peripheral vision, the glaucoma is progressing, necessitating a change in treatment strategy to preserve the remaining sight. 

What We’ll Discuss in This Article 

• The role of Guided Progression Analysis (GPA) in structural and functional testing. 

• How specialists use the “rate of change” to predict future vision loss. 

• Comparing successive OCT scans to identify microscopic thinning of the nerve. 

• The importance of visual field maps in tracking the expansion of blind spots. 

• Why intraocular pressure fluctuations are a warning sign of instability. 

• The clinical significance of disc haemorrhages in progressive cases. 

• Frequently asked questions about monitoring intervals and treatment adjustments. 

The Concept of “Rate of Change” 

The most important question a specialist asks is not “How bad is the glaucoma?” but “How fast is it moving?” Every individual loses a very small amount of optic nerve tissue as part of the natural ageing process. However, in glaucoma, this loss happens much more rapidly. Specialists use a series of tests over several months or years to calculate the specific rate of change for each patient. By plotting this data on a graph, they can see a trend line. If the line shows a significant downward slope, it indicates that the current treatment is not sufficient to halt the disease. 

According to clinical standards from the Royal College of Ophthalmologists, this rate of change is used to estimate the patient’s risk of developing a significant visual disability during their lifetime. For example, a slow rate of loss in an 85-year-old might be acceptable, whereas the same rate in a 40-year-old would be considered an emergency because they have many more years of life to protect. This personalised approach ensures that treatment is adjusted based on the individual’s specific risk of future blindness. 

Structural Progression: Monitoring the Nerve with OCT 

Optical Coherence Tomography (OCT) is the primary tool for identifying structural progression. This scan provides a microscopic measurement of the thickness of the retinal nerve fibre layer (RNFL). When you have a follow up appointment, the specialist uses software called Guided Progression Analysis (GPA) to compare your new scan to your original baseline. The computer looks for areas where the tissue has become thinner than can be explained by natural ageing or the “noise” of the machine. 

If the OCT shows a consistent decrease in the thickness of the neuroretinal rim or the peripapillary RNFL, it is a definitive sign of progression. This structural change often occurs before the patient notices any change in their vision. Research by the Association of Optometrists notes that structural thinning is a primary indicator for specialists to increase the potency of eye drops or consider surgical options. By identifying the damage at the structural level, clinicians can hit the brakes on the disease before it results in a functional blind spot. 

Functional Progression: Visual Field Mapping 

While OCT looks at the hardware of the eye, visual field testing (perimetry) looks at its performance. Functional progression is identified when the maps of your peripheral vision show that existing blind spots are getting deeper or wider, or if entirely new blind spots are appearing. Like the OCT, modern visual field machines have built in GPA software that compares the current results to a series of previous tests. 

Identifying functional progression can be challenging because a patient’s performance on a visual field test can vary based on their tiredness or concentration level. This is why specialists usually require at least three or four tests over a period to confirm a “true” progression. According to Patient.info, if a functional loss is confirmed, it is a clear sign that the optic nerve damage has reached a stage where it is impacting the patient’s visual world. This often triggers a shift in treatment, such as a referral for Selective Laser Trabeculoplasty (SLT). 

Pressure Fluctuations and Instability 

Although glaucoma is defined by nerve damage, intraocular pressure (IOP) remains the primary gauge of stability. If a patient’s pressure was stable at 14 mmHg but is now consistently reading at 19 mmHg, the specialist will view this as a sign of potential progression. Even if the scans haven’t changed yet, a rising pressure indicates that the current treatment is losing its effectiveness. 

Fluctuations in pressure are also a concern. If the pressure is low during a morning appointment but high during an afternoon check, the “peaks” in pressure could be causing damage while the patient is away from the clinic. UK specialists often look at these patterns to decide if a patient needs a different type of eye drop that provides better 24-hour control. Stability in eye pressure is the first goal of treatment; if the pressure is not stable, the disease is rarely considered to be under control. 

Correlating Structure and Function 

The most confident way a specialist decides that glaucoma is progressing is when both the structural scans (OCT) and the functional tests (visual field) show damage in the same area. For example, if an OCT scan shows thinning in the bottom half of the optic nerve, the specialist would expect to see a blind spot appearing in the top half of the patient’s visual field (as the eye’s image is inverted). 

When structure and function “match,” it provides a high level of diagnostic certainty. However, it is common for one to show change before the other. This is why UK clinical guidelines from NICE advocate for a dual monitoring approach. By looking at both the physical health of the nerve and the patient’s actual sight, the specialist can create a safety net that catches progression from any angle. This comprehensive oversight is the best way to ensure that a patient maintains their independence and quality of life. 

Treatment Escalation Based on Progression 

If a specialist confirms that glaucoma is progressing, they will escalate the treatment plan. This does not always mean a failure of the current drops; it simply means the disease has reached a point where it requires more aggressive management. Escalation steps in the UK typically include: 

• Adding a second eye drop: Using a different class of medication to improve fluid drainage. 

• Switching to preservative free drops: To reduce eye surface irritation and improve the patient’s ability to stay on the treatment. 

• Laser Therapy (SLT): A quick procedure to improve the outflow of fluid from the eye. 

• Surgical intervention: Procedures like a trabeculectomy or a “MIGS” (Minimally Invasive Glaucoma Surgery) to create a new drainage pathway. 

The decision to escalate is always a collaborative one between the specialist and the patient, focusing on the goal of halting the progression and protecting the vision for the long term. 

Method of Check	Evidence of Progression	Specialist Action
OCT Scan	Microscopic thinning of the RNFL	Reviews target pressure and drop routine
Visual Field	New or deeper peripheral blind spots	Considers laser or additional medication
Disc Inspection	Splinter haemorrhages on the nerve	Schedules more frequent monitoring
Tonometry	Pressure rising above the target level	Adjusts or adds eye drops
GPA Software	Statistical downward trend over time	Escalates to more intensive clinical care

Summary 

Specialists decide if glaucoma is progressing by analyzing the “rate of change” in a patient’s eye health over several visits. They use OCT scans to identify structural thinning of the nerve and visual field tests to map functional blind spots. Physical signs like disc haemorrhages and fluctuations in eye pressure also serve as critical warnings. In the UK, this longitudinal monitoring allows clinicians to escalate treatment proactively, ensuring that the disease is managed aggressively enough to prevent significant vision loss during the patient’s lifetime. 

Authority snapshot 

This article provides a clinical overview of the methodologies used by UK ophthalmic specialists to identify and manage the progression of glaucoma. The content is developed in strict accordance with the medical standards and monitoring protocols provided by the NHS and the Royal College of Ophthalmologists to ensure accuracy and patient safety. Dr. Stefan, a London based physician with a focus on chronic disease management, has reviewed this article to confirm its clinical accuracy and its alignment with current UK protocols for longitudinal eye care.